OBI decided to terminate OBI-822 Phase 3 study based on DSMB's recommendation and to redirect resources towards ADCs development

Date of occurrence of the event:2025/04/23 New drug name or code: The active cancer immunotherapy Adagloxad Simolenin (OBI-822)/OBI-821 Indication: Adagloxad Simolenin (OBI-822) is a therapeutic cancer vaccine classified as an active cancer immunotherapy. Globo H-KLH conjugate triggers an immune response against solid tumors when injected into humans. OBI-821 is an adjuvant that is administered with […]